Sugentech Shares Outstanding vs. Debt To Equity
Considering the key profitability indicators obtained from Sugentech's historical financial statements, Sugentech may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Sugentech's ability to earn profits and add value for shareholders.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Please note, there is a significant difference between Sugentech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sugentech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sugentech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
For Sugentech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Sugentech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Sugentech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Sugentech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Sugentech over time as well as its relative position and ranking within its peers.
Sugentech |
Sugentech Debt To Equity vs. Shares Outstanding Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Sugentech's current stock value. Our valuation model uses many indicators to compare Sugentech value to that of its competitors to determine the firm's financial worth. Sugentech is rated second in shares outstanding category among its peers. It also is rated second in debt to equity category among its peers . The ratio of Shares Outstanding to Debt To Equity for Sugentech is about 219,730,769 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Sugentech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Sugentech's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Sugentech Debt To Equity vs. Shares Outstanding
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Sugentech |
| = | 11.43 M |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Sugentech |
| = | 0.05 % |
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Sugentech Debt To Equity Comparison
Sugentech is currently under evaluation in debt to equity category among its peers.
Sugentech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Sugentech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Sugentech will eventually generate negative long term returns. The profitability progress is the general direction of Sugentech's change in net profit over the period of time. It can combine multiple indicators of Sugentech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Sugentech Inc. develops and sells in-vitro diagnostic systems and products based on biotechnology, information technology, and nanotechnology in South Korea and internationally. Sugentech Inc. was founded in 2011 and is headquartered in Daejeon, South Korea. Sugentech is traded on Korean Securities Dealers Automated Quotations in South Korea.
Sugentech Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Sugentech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Sugentech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Sugentech's important profitability drivers and their relationship over time.
Use Sugentech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sugentech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sugentech will appreciate offsetting losses from the drop in the long position's value.Sugentech Pair Trading
Sugentech Pair Trading Analysis
The ability to find closely correlated positions to Sugentech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sugentech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sugentech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sugentech to buy it.
The correlation of Sugentech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sugentech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sugentech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sugentech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Sugentech position
In addition to having Sugentech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cancer Fighters Thematic Idea Now
Cancer Fighters
Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. The Cancer Fighters theme has 60 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cancer Fighters Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Sugentech Stock
To fully project Sugentech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Sugentech at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Sugentech's income statement, its balance sheet, and the statement of cash flows.